455 results on '"Yerushalmi R"'
Search Results
2. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study
3. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
4. Pregnancy After Breast Cancer in Young BRCA Carriers
5. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
6. Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation
7. 192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)
8. 186O Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2–positive (HER2+) metastatic breast cancer (mBC)
9. P169 Clinical outcomes in patients (pts) with estrogen receptor (ER)+ stage I breast cancer (BC) and Recurrence Score (RS) 26–30: Real-world data
10. 149P Clinical outcomes in ER+ breast cancer patients with recurrence score 26-30-guided therapy: Real-world data
11. 152P Molecular characterization by the 21-gene breast cancer (BC) Recurrence Score (RS) test of BRCA1/2 mutation carriers (mBRCA1/2) versus the general BC patient (pt) population
12. 1815O Breastfeeding after breast cancer in young BRCA carriers: Results from an international cohort study
13. Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers
14. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation
15. Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations
16. Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies
17. Atomic and Molecular Layer Deposition of Chiral Thin Films Showing up to 99% Spin Selective Transport
18. P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
19. Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer
20. Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?
21. VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
22. Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers
23. Breast carcinoma—rare types: review of the literature
24. Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study
25. Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials
26. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis
27. Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced
28. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
29. Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity
30. 388P Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC)
31. 369P The impact of germline BRCA mutations in locally advanced, triple-negative breast cancer (TNBC) treated with platinum- based neoadjuvant chemotherapy
32. SURVIVAL ADVANTAGE FOR PATIENTS WITH AML/MDS GIVEN ALLOGENEIC SCT USING MYELOABLATIVE VERSUS REDUCED INTENSITY CONDITIONING (RIC) MAY BECOME APPARENT 5-10 YEARS AFTER TRANSPLANTATION: RIC STUDIES MAY NEED TO BE REVISITED AFTER LONG-TERM FOLLOW-UP: PH-O073
33. MISSING HLA C GROUP 1 LIGAND IN PATIENTS WITH AML AND MDS IS ASSOCIATED WITH REDUCED RISK OF RELAPSE AND IMPROVED SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION WITH FLUDARABINE AND TREOSULFAN REDUCED TOXICITY CONDITIONING: PH-O046
34. Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma
35. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan
36. National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study
37. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity
38. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome
39. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up
40. Fludarabine and treosulfan conditioning for allogeneic stem cell transplantation; a dose- intense regimen with limited toxicity: P961
41. Cyclosporine and methotrexate compared with cyclosporine and mycophenolate as GvHD prevention regimens in allogeneic stem cell transplantation from unrelated donors; relative outcomes are dependent on disease status at transplantation: P447
42. Reduced toxicity myeloablative conditioning regimens compared with standard myeloablative conditioning prior to allogeneic stem cell transplantation in AML and MDS; more favourable toxicity profile but more limited leukaemia control in advanced disease: O289
43. Pretransplantation administration of anti-thymocyte globulin as part of the conditioning induces T regulatory cells - Clinical implications: O426
44. Treatment of donor graft failure with autologous or allogeneic stem cell boost or a second allogeneic transplantation based on chimerism testing
45. Fludarabine and treosulfan; a novel reduced-toxicity regimen with effective anti-leukaemia activity in patients with AML and MDS
46. The concordance of treatment decision guided by oncotype and the PREDICT tool in early stage breast cancer
47. Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer
48. BASELINE CLINICAL AND PET-CT TUMOR BURDEN PARAMETERS DO NOT PREDICT OUTCOME OF RELAPSE/REFRACTORY AGGRESSIVE B CELL LYMPHOMA PATIENTS TREATED WITH ANTI-CD19 CAR T-CELLS
49. PS1030 COMPLETE REMISSION WITH INCOMPLETE BLOOD COUNT RECOVERY IS A STRONG PREDICTOR OF NON-RELAPSE MORTALITY IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
50. PS1547 LONG-ACTING G-CSF (LIPEGFILGRASTIM, “LONQUEX”) FOR STEM CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.